Long-term outcome for lymph node-positive prostate cancer.
Although the number of men with lymph node-positive prostate cancer has declined, it is still significant and the challenge remains on how best to treat these patients. Only long-term follow-up can give a true indication of the outcome in prostate cancer. We evaluated our experience in treating lymph node-positive prostate cancer with a median follow-up of 10.2 years. The overall 5-year survival was 78% and the 10-year survival was 56%. Length of tumor control depends on the type of treatment given. Adding androgen ablation improves the duration of control dramatically, although optimal timing is still uncertain.
Swanson
G P
GP
The Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. gswanson@ctrc.net
Riggs
M W
MW
Herman
M
M
D000230:Adenocarcinoma / Q000401:mortality* / Q000556:secondary* / Q000628:therapy; D000328:Adult; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002423:Cause of Death; D003131:Combined Modality Therapy; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D018714:Radiotherapy, Adjuvant; D016879:Salvage Therapy; D016019:Survival Analysis; D015996:Survival Rate; D017741:Survivors / Q000706:statistics & numerical data
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal